斯奇康防治毛细支气管炎后反复喘息的研究  

Study of intervening therapy after bronchiolitis by BCG-PSN

作　　者：钟礼立[1] 李云[1] 

机构地区：[1]湖南省人民医院儿科,湖南长沙410008

出　　处：《中国现代医学杂志》2004年第5期88-90,共3页China Journal of Modern Medicine

摘　　要：目的　评价斯奇康干预治疗毛细支气管炎防止其后反复喘息的疗效并探讨其作用机制。方法　毛细支气管炎 70例 ,(其中有特应症者 31例 ,无特应症者 39例 )。从有特应症者 ,无特应症者中各随机抽取一半组成斯奇康治疗组 (B1组 ) ,余下组成非治疗组 (B2 组 ) ;正常对照组 39例 (A组 )。三组均测定其PBMC培养上清液中IL - 4 ,IFN -γ ,及血清IgE值。B组给予斯奇康治疗 6个月 ,6个月后三组再抽血查PBMC培养上清液中IL - 4 ,IFN -γ且随访半年登记愈后反复喘息次数。结果　急性期B1组和B2 组较A组比IL -4 ,IL - 4 /IFN -γ及血清IgE水平均显著升高 ;治疗 6个月后B2 组较A组 ,B1组比IL - 4水平及IL - 4 /IFN-γ比值显著升高 ,B1组较A组比上述指标均无显著差异。随访半年后发现B1组发生反复喘息率较B2组显著下降。结论　斯奇康对预防毛细支气管炎后反复喘息临床有一定疗效。其干预治疗的机制可能与其调节TH1及TH2细胞因子使之趋于平衡有关。Objective: To evaluate the value of intervening therapy with BCG-PSN following bronchiolitis and explore the mechanism.Methods:70 cases with bronchiolifis (31cases atopy+ and 39 cases atopy-) . Half of atopy+ patients and half of atopy- patients were selected randomly to form the B 1 group, the rest form the B 2 group, 39 healthy cases form the control group. The levels of IL-4, IFN- γ in cultured supematants of PBMC and IgE in blood serum were assayed in all groups. Patients in B1 group were given BCG-PSN therapy for 6 months, IL-4, IFN-γ in cultured supernatants of PBMC were measured again six months later. Recurrent wheezing times were investigated for a year. Results: Compared with control group, the levels of IL-4, IL-4/IFN-γ and serum IgE in B 1 group and B 2 group were significantly in creased in acute phase. Six month later, The levels of IL-4, IL-4/IFN-γ in B 2 group were higher than B1 group and control group. The levels of IL-4, IL-4/IFN-γand IFN-γ in B1 groups have no statistically difference with control group. The incidence of recurrent wheezing B 2 group was statistically higher than those in B1group.Conclusions: BCG-PSN is clinically effective in preventing recurrent wheezing following bronchiolitis. The intervening mechanism may be related to its regulation of TH1 and TH2 cytokines to reach their stability.

关 键 词：毛细支气管炎 白介素-4 Γ干扰素 免疫球蛋白E 斯奇康 干预治疗 

分 类 号：R725.6[医药卫生—儿科]